Literature DB >> 6202346

In vitro activation of the contact (Hageman factor) system of plasma by heparin and chondroitin sulfate E.

Y Hojima, C G Cochrane, R C Wiggins, K F Austen, R L Stevens.   

Abstract

A large number of negatively charged macromolecules, including DNA, glycosaminoglycans, and proteoglycans, were tested as possible activators of the contact (Hageman factor) system in vitro. Activation was assessed by conversion of prekallikrein to kallikrein, as determined by amidolytic assay and by cleavage of 125I-Hageman factor into 52,000- and 28,000-dalton fragments. Of particular interest to these studies, heparin proteoglycan and glycosaminoglycan from rat peritoneal mast cells, and squid chondroitin sulfate E, which is representative of the glycosaminoglycan from cultured mouse bone marrow derived mast cells, induced the reciprocal activation between Hageman factor and prekallikrein. In addition, naturally occurring heparin glycosaminoglycans from pig mucosa, bovine lung, and rat mast cells also induced activation. In contrast, native connective tissue matrix glycosaminoglycans and proteoglycans from several sources were inactive, although when one such chondroitin sulfate was further sulfated in vitro, it gained activity. When the negative charge of the activating agents was blocked by the addition of hexadimethrine bromide, the cleavage of 125I-Hageman factor in the presence of prekallikrein was prevented. The active negatively charged macromolecules induced cleavage of 125I-high molecular weight kininogen in normal plasma but not in Hageman factor-deficient or prekallikrein-deficient plasmas. Reconstitution of prekallikrein-deficient plasma with purified prekallikrein restored the kininogen cleavage upon addition of the active proteoglycans. These results suggest that both heparin from connective tissue mast cells and highly sulfated chondroitin sulfate E from cultured mouse bone marrow derived mast cells (which are considered synonomous with mucosal mast cells) could activate the contact system of plasma subsequent to an activation secretion response.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6202346

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  34 in total

Review 1.  Implication of GnT-V in cancer metastasis: a glycomic approach for identification of a target protein and its unique function as an angiogenic cofactor.

Authors:  N Taniguchi; S Ihara; T Saito; E Miyoshi; Y Ikeda; K Honke
Journal:  Glycoconj J       Date:  2001 Nov-Dec       Impact factor: 2.916

Review 2.  FXII.

Authors:  G Fuhrer; M J Gallimore; W Heller; H E Hoffmeister
Journal:  Blut       Date:  1990-11

3.  Specific types of activated Factor XII increase following thrombolytic therapy with tenecteplase.

Authors:  Volker Pönitz; David Pritchard; Heidi Grundt; Dennis Winston T Nilsen
Journal:  J Thromb Thrombolysis       Date:  2006-12       Impact factor: 2.300

4.  Changes of plasma activated Factor XII type A (XIIaA) concentrations following percutaneous coronary intervention (PCI).

Authors:  Volker Pönitz; David Pritchard; Heidi Grundt; Mai-Britt Mehus; Dennis Winston T Nilsen
Journal:  J Thromb Thrombolysis       Date:  2007-05-11       Impact factor: 2.300

5.  Bradykinin in health and disease: proceedings of the Bradykinin Symposium 2012, Berlin 23-24 August 2012.

Authors:  Markus Magerl; Michael Bader; Anne Gompel; Kusumam Joseph; Allen P Kaplan; Georg Kojda; Thomas Renné; Markus Wirth; Marcus Maurer; Martin K Church
Journal:  Inflamm Res       Date:  2013-12-08       Impact factor: 4.575

Review 6.  Complement, Kinins, and Hereditary Angioedema: Mechanisms of Plasma Instability when C1 Inhibitor is Absent.

Authors:  Allen P Kaplan; Kusumam Joseph
Journal:  Clin Rev Allergy Immunol       Date:  2016-10       Impact factor: 8.667

Review 7.  Bradykinin formation. Plasma and tissue pathways and cellular interactions.

Authors:  A P Kaplan; K Joseph; Y Shibayama; Y Nakazawa; B Ghebrehiwet; S Reddigari; M Silverberg
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

8.  Discovery of an intrinsic tenase complex inhibitor: Pure nonasaccharide from fucosylated glycosaminoglycan.

Authors:  Longyan Zhao; Mingyi Wu; Chuang Xiao; Lian Yang; Lutan Zhou; Na Gao; Zi Li; Jun Chen; Jianchao Chen; Jikai Liu; Hongbo Qin; Jinhua Zhao
Journal:  Proc Natl Acad Sci U S A       Date:  2015-06-22       Impact factor: 11.205

Review 9.  The initiation and effects of plasma contact activation: an overview.

Authors:  Lisha Lin; Mingyi Wu; Jinhua Zhao
Journal:  Int J Hematol       Date:  2016-11-15       Impact factor: 2.490

10.  Roles of galactose and sulfate residues in sulfatides for their antagonistic functions in the blood coagulation system.

Authors:  M Kyogashima; T Sakai; J Onaya; A Hara
Journal:  Glycoconj J       Date:  2001-03       Impact factor: 2.916

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.